Marcin Frąckiewicz, Author at TechStock²

Google’s Pixel 10 Pro Fold Shakes Up the Smartphone Wars with AI Tricks, Durability & Bold Design

Pixel 10 Pro Fold: Google’s AI-Powered Foldable Flagship Google’s new Pixel 10 Pro Fold is the star of its 2025 lineup – a device that blends cutting-edge hardware with Google’s latest AI software. This foldable phone is branded as the “Pro Fold”

8 October 2025

Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real?

Stock Performance: The 2025 Rollercoaster Ride Xenetic’s stock was relatively quiet for most of 2025 until early October, when it suddenly erupted. By Oct 8, 2025, XBIO had skyrocketed to levels not seen in years. On that day alone, the stock soared

8 October 2025

2025 Outlook · Biotechnology · Financial News · NASDAQ:XBIO · Pharma Investing · Stock Market

Plant-Based Food Stock Goes Crypto: Above Food (ABVE) Skyrockets in 2025

Above Food Ingredients Inc. is a Canadian plant-based food tech company that went public via SPAC merger in 2024 stocktwits.com. In 2025, its stock ABVE has been on a wild ride – climbing from penny-stock levels to over $4, an almost 8-fold increase in under a year

8 October 2025

Cryptocurrency · Financial News · Investment Trends · NASDAQ:ABVE · Plant-Based Foods · Stock Market

Cipher Mining (CIFR) Stock Skyrockets on AI Pivot & Bitcoin Boom – Next Crypto Powerhouse?

Company Overview: Operations & Business Model Cipher Mining Inc. is a pure-play Bitcoin miner operating industrial-scale data centers with a focus on ultra-low-cost power ts2.tech. The company strategically locates its facilities in regions with cheap, renewable-rich electricity (e.g. West Texas), often building behind-the-meter or

8 October 2025

Artificial Intelligence · Cryptocurrency · Financial News · Investment Strategies · NASDAQ:CIFR · Stock Market

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 biospace.com; ~16 patients treated in launch year nasdaq.com. Sold to US WorldMeds (2025) adaptimmune.com Letetresgene (lete-cel, NY-ESO-1) MRCLS and synovial sarcoma (advanced solid tumors) Phase

8 October 2025

Biotech · Company Analysis · Financial News · Investing · NASDAQ:ADAP · Stock Market

Snowflake Stock Soars on AI Boom – Inside SNOW’s 2025 Rally and What’s Next

Below, we dive deeper into each of these areas – from Snowflake’s business model and financials to the latest news, analyst insights, competitive dynamics, and what to expect going forward. Company Overview and Business Model Snowflake Inc. is a cloud data

8 October 2025

Artificial Intelligence · Financial Analysis · Investing · NYSE:SNOW · Stock Market · Technology

CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

Sources: Official company reports and press releases; Yahoo Finance and Zacks Investment Research; Reuters and CNBC interviews; TS2 Tech stock analysis and cybersecurity news ts2.tech nasdaq.com markets.financialcontent.com marketbeat.com ts2.tech siliconangle.com ts2.tech. These provide the latest financial data, expert commentary, and industry context

8 October 2025

Cybersecurity · Financial News · Investment Analysis · NASDAQ:CRWD · Stock Market · Technology Trends

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Detailed Report 1. Stock Performance and Valuation Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025 (the last trading day before the U.S. Columbus Day holiday), the stock closed at $27.34, down

8 October 2025

Biotechnology · Company News · Financial Analysis · Investing · NASDAQ:BNTX · NASDAQ:MRNA · NYSE:MRK · Stock Market

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Quick Facts (as of 8 Oct 2025) Recent Performance and News Phase 1 data fuels rally Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran (nex‑z), an in‑vivo CRISPR therapy for transthyretin (ATTR) amyloidosis. A GlobeNewswire release (Sept 25 2025) reported that

8 October 2025

Biotechnology · Company Analysis · Gene Editing · Investment Opportunities · NASDAQ:NTLA · Stocks

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

Stock Price, Volume and Sentiment According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior

8 October 2025

Biotechnology · Gene Editing · Investment Analysis · Market Trends · NASDAQ:CRSP · Stocks

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to

8 October 2025

Biotechnology · Gene Editing · Investment Analysis · NASDAQ:NTLA · Pharmaceutical News · Stock Market

TSMC Stock Soars on AI Boom: Record Highs, Big Ambitions & Geopolitical Risks (Oct 2025 Update)

Overview: TSMC’s Business and Recent Performance Taiwan Semiconductor Manufacturing Co. (TSMC) is the world’s largest contract chipmaker (pure-play foundry), producing advanced semiconductors for clients like Apple, NVIDIA, AMD, and many others taiwannews.com.tw ts2.tech. Rather than selling its own branded chips, TSMC

8 October 2025

Artificial Intelligence · Geopolitics · Investment Strategies · NYSE:TSM · Stock Market · Technology News